Kenneth Glad
A nutrient long associated with bone strength is now being examined through a different lens. Researchers suggest it could quietly influence how well cancer therapies perform, raising questions about its broader role in care. The findings also point to something more practical: whether a widely available supplement could narrow treatment gaps in resource-limited settings.
According to research published in Nutrition and Cancer, a team at São Paulo State University investigated whether vitamin D supplementation could support chemotherapy in breast cancer patients.
The study, backed by FAPESP, followed 80 women aged over 45 undergoing pre-surgical chemotherapy at a teaching hospital in Brazil.
Instead of focusing solely on clinical outcomes, the researchers also underscored the accessibility of the intervention, noting that many therapies designed to enhance chemotherapy remain costly or out of reach in public health systems.
This framing reflects a broader challenge in oncology: improving outcomes without significantly increasing treatment costs.
Interpreting the results
The difference between the groups was notable. Patients who received vitamin D alongside chemotherapy were far more likely to show no detectable signs of cancer after treatment, a clinical outcome known as a complete response.
While this does not necessarily mean the disease is cured, it is often linked to better long-term prognosis.
Overall, the response rate in the supplemented group was nearly twice that of those who received a placebo.
“Even with a small sample of participants, it was possible to observe a significant difference in the response to chemotherapy. In addition, the dosage used in the research [2,000 IU per day] is far below the target dose for correcting vitamin D deficiency, which is usually 50,000 IU per week,” said Eduardo Carvalho-Pessoa, as reported in Nutrition and Cancer.
Many participants began treatment with insufficient levels of the nutrient, which may have influenced how their bodies responded to therapy.
Why researchers are cautious
Vitamin D is widely recognized for its role in maintaining bone health, but scientists increasingly link it to immune system activity. This connection could help explain why supplementation might support the body during cancer treatment.
“With supplementation, levels increased throughout chemotherapy treatment, which reinforces a possible contribution to the patients’ recovery,” Carvalho-Pessoa told FAPESP.
Even so, the researchers stress that the findings are preliminary. The relatively small sample size means further investigation is needed before drawing firm conclusions or changing clinical practice.
“These are encouraging results that justify a new round of studies with a larger number of participants. This will allow a greater understanding of the role of vitamin D in increasing the response to chemotherapy treatment and, consequently, in the greater likelihood of breast cancer remission,” he said.
If confirmed in larger trials, the approach could influence treatment planning, particularly in healthcare systems seeking effective but affordable supportive therapies.
Sources: Nutrition and Cancer, Agência FAPESP
